- Home
- SND vs CNTX Comparison
SND vs CNTX Comparison
Compare SND & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SND
- CNTX
- Stock Information
- Founded
- SND 2011
- CNTX 2015
- Country
- SND United States
- CNTX United States
- Employees
- SND N/A
- CNTX N/A
- Industry
- SND Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- SND Industrials
- CNTX Health Care
- Exchange
- SND Nasdaq
- CNTX Nasdaq
- Market Cap
- SND 86.8M
- CNTX 78.0M
- IPO Year
- SND 2016
- CNTX 2021
- Fundamental
- Price
- SND $2.06
- CNTX $0.78
- Analyst Decision
- SND Hold
- CNTX Strong Buy
- Analyst Count
- SND 2
- CNTX 6
- Target Price
- SND $2.63
- CNTX $6.50
- AVG Volume (30 Days)
- SND 139.3K
- CNTX 94.5K
- Earning Date
- SND 05-13-2025
- CNTX 05-07-2025
- Dividend Yield
- SND 4.85%
- CNTX N/A
- EPS Growth
- SND N/A
- CNTX N/A
- EPS
- SND 0.08
- CNTX N/A
- Revenue
- SND $311,372,000.00
- CNTX N/A
- Revenue This Year
- SND N/A
- CNTX N/A
- Revenue Next Year
- SND N/A
- CNTX N/A
- P/E Ratio
- SND $26.72
- CNTX N/A
- Revenue Growth
- SND 5.20
- CNTX N/A
- 52 Week Low
- SND $1.73
- CNTX $0.55
- 52 Week High
- SND $2.80
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- SND 46.99
- CNTX 45.08
- Support Level
- SND $1.99
- CNTX $0.74
- Resistance Level
- SND $2.16
- CNTX $0.85
- Average True Range (ATR)
- SND 0.11
- CNTX 0.09
- MACD
- SND 0.01
- CNTX -0.02
- Stochastic Oscillator
- SND 29.03
- CNTX 13.67
About SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.